Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Modular Medical (NASDAQ:MODD) Stock Surges 28% Ahead of Pivot Launch

Shares of Modular Medical (NASDAQ:MODD) rocketed higher, thrusting the tiny diabetes-device maker onto the market's most-active small-cap lists. The move turns a stock with aMarket Valuerecently near $16 million into a momentum favorite, even though the company has not tied the latest surge to …

Vinay Lochav | 19 August 2026

Nuvectis Pharma (NASDAQ:NVCT) Stock Jumps 10% on Financing and China Approval

Nuvectis Pharma (NASDAQ:NVCT) advanced sharply in August 2026, with the stock indicating up roughly 9.6% in premarket action near $20.30 after closing at $19.23. The move extended a powerful multi-month run that has lifted the precision-oncology developer's market capitalization to about $627 million, up …

Vinay Lochav | 19 August 2026

Nuvation Bio (NYSE:NUVB) Stock Climbs 7% on JPMorgan Overweight Call

Nuvation Bio (NYSE:NUVB) is rallying, with shares up about 7.4% after a new bullish call fromWall Streetput a spotlight on the oncology company's commercial launch and its expanding pipeline. The move follows JPMorgan's decision to begin coverage of the stock with an Overweight rating …

Vinay Lochav | 19 August 2026

Psyence Biomedical (NASDAQ:PBM) Stock Rockets 24% on Ibogaine Policy News

Psyence Biomedical (NASDAQ:PBM) shares rocketed higher as the clinical-stage psychedelics developer moved back into the spotlight on renewed U.S. policy momentum around ibogaine. On August 19, 2026, the company issued a release welcoming the latest U.S. administration action to accelerate ibogaine development, tying its …

Vinay Lochav | 19 August 2026

AVITA Medical (NASDAQ:RCEL) Stock Rips 25% on PermeaDerm Cost-Savings Data

AVITA Medical (NASDAQ:RCEL) shares surged after the regenerative wound-care company released results from a randomized controlled trial showing its PermeaDerm biosynthetic wound matrix delivered clinical outcomes comparable to cadaveric allograft while costing about 70% less. The data, announced on August 18, 2026, gave investors …

Vinay Lochav | 19 August 2026

Tectonic Therapeutic (NASDAQ:TECX) Stock Climbs 8% Ahead of Phase 2 Data

Shares of Tectonic Therapeutic, Inc. (NASDAQ:TECX) rose about 8.2% on Wednesday, extending a run of buying interest in the clinical-stage biotech even without a fresh, company-specific announcement tied to the session. The move reflects continued investor attention on TX45, the company's lead drug candidate.

Vinay Lochav | 19 August 2026

Nutriband (NASDAQ:NTRB) Stock Jumps 7% on AVERSA Fentanyl Patch Momentum

Nutriband Inc. (NASDAQ:NTRB) rose about 6.8% in a fresh advance, drawing renewed attention to the small transdermal-pharmaceuticals developer and its lead candidate, an abuse-deterrent fentanyl patch. No single new company announcement was confirmed as the exact catalyst for the move, which appears driven more …

Vinay Lochav | 19 August 2026

Obsidian Therapeutics (NASDAQ:OBX) Stock Surges 14% After Nasdaq Debut

Obsidian Therapeutics (NASDAQ:OBX) is climbing, with the newly public cancer-cell-therapy developer gaining about 14% and popping onto momentum screens. The move comes just weeks after Obsidian completed a reverse merger with Galera Therapeutics, closed an oversubscribed $350 million private placement and began trading on …

Vinay Lochav | 19 August 2026

QT Imaging (NASDAQ:QTI) Stock Surges 8% on Doubled Revenue

Shares of QT Imaging Holdings, Inc. (NASDAQ:QTI) surged about 7.8% in August 2026, drawing renewed attention to the small-cap medical-imaging company after it posted strong revenue growth and a series of operational milestones. The move follows the company's second-quarter report, though the exact session-level …

Vinay Lochav | 19 August 2026

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Rockets 37% on Thin Float

China SXT Pharmaceuticals (NASDAQ:SXTC) has become a magnet for momentum traders, ripping roughly 37% in a session that extended a wild run for the traditional Chinese medicine micro-cap. The move follows a dramatic reshaping of the company's share structure and a stretch of extremeVolatilityin …

Vinay Lochav | 19 August 2026
Support

Hi! How can we help you today?

Loading…